INmune Bio (INMB) Financials

$2.44

$0.17 (7.49%)

As on 04-Sep-2026 19:39EDT

Market cap

$68 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

3.1

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	0.05	0.01	0.16	0.37	0.18
Cost of Revenue	0.14	--	--	--	--	--
Gross Profit	-0.14	0.05	0.01	0.16	0.37	0.18
Operating Expenses	20.09	30.92	42.65	29.90	26.33	29.33
Operating Profit (EBIT)	-20.20	-30.87	-42.64	-29.74	-25.95	-29.15
Other Income	--	--	--	--	--	-1.19
Profit before Tax	-18.42	-45.93	-42.08	-30.01	-27.30	-30.34
Provision for Tax	--	--	--	-29.74	1.35	1.19
Profit after Tax (Net Income)	-18.42	-45.93	-42.08	-30.01	-28.65	-30.34
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-27.30	-30.34

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	20.36	23.52	32.10	38.14	60.10	80.23
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.59	0.41	0.24	0.40	10.77	15.36
Current Liabilities	5.89	8.42	7.22	18.47	10.92	4.36
Total Liabilities	32.74	32.35	39.56	57.00	81.80	99.95

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	3.05	2.46	16.90	17.06	17.12	17.34
Current Assets	23.80	29.89	22.66	39.94	64.68	82.61
Total Assets	32.74	32.35	39.56	57.00	81.80	99.95
Total Debt*	1.41	1.03	0.38	10.44	15.31	15.23
Net Current Assets	17.91	21.47	15.44	21.48	53.76	78.25

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-22.58	-33.36	-11.98	-22.69	-28.50
Cash Flow from Investing Activities	--	-1.04	--	--	--	-15.00
Cash from Financing Activities	--	27.61	18.21	-4.23	0.73	96.36
Net Cash Inflow / Outflow	--	--	--	--	-21.96	52.84

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.69	-1.73	-1.89	-1.67	-1.60	-1.75
Cash EPS ($)	--	-1.72	-1.89	-1.67	-1.60	-1.75
Adjusted Book Value ($)	--	0.88	1.44	2.12	3.35	4.63
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.85	-1.50	-0.67	-1.27	-1.64
Free Cash Flow per Share ($)	--	-0.89	-1.50	-0.67	-1.27	-2.51

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-161.06	-103.83	-48.40	-33.53	-45.16
ROE (%)	-83.93	-165.16	-119.83	-61.09	-40.83	-51.00
ROA (%)	-46.62	-127.75	-87.16	-43.24	-31.53	-43.16
EBIT Margin (%)	--	-91,866.00	-300,585.71	-19,360.00	-6,938.77	-16,106.63
Net Margin (%)	--	-91,866.00	-300,585.71	-19,360.00	-7,659.63	3,015.90
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	2.57	-0.91	-0.59	1.07	15.58
EBIT Growth (%)	2.74	-9.15	-40.24	-15.63	10.98	-138.42
Net Profit Growth (%)	66.82	-9.15	-40.24	-4.75	5.58	-150.76
EPS Growth (%)	72.25	0.09	-0.13	-0.05	0.09	-0.87
Book Value Growth (%)	-38.49	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.90	-2.47	-6.74	-3.97	-5.83
Price / Book Value	3.12	1.76	3.24	5.30	1.89	2.20
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-5.31	-0.39	-2.01	-661.86	-2.81	-3.86
Close Price ($)	1.63	1.56	4.67	11.26	6.34	10.20
High Price ($)	3.24	11.64	14.74	11.78	11.78	30.37
Low Price ($)	1.09	1.38	4.32	5.87	4.63	9.23
Market Cap ($ Cr)	67.72	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.04	0.01	0.27	0.25	0.19
Short term debt to equity ratio	0.04	0.03	0.00	0.26	0.08	0.00
Current Ratio	4.04	3.55	3.14	2.16	5.92	18.95
Quick Ratio	4.04	--	--	--	5.92	20.21
Interest Coverage	--	--	--	--	-19.25	-24.56

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	9,082.00	10,064.29	1,575.48	2,262.30	3,040.88
Asset Turnover	--	0.00	0.00	0.00	0.00	0.00
Receivable days	--	21,732.38	50,234.92	12,846.20	6,819.14	7,368.57
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.